The hematopoietic-specific β1-tubulin is naturally resistant to 2-methoxyestradiol and protects patients from drug-induced myelosuppression

Cell Cycle

Volumn 8, Issue 23, 2009, Pages 3914-3924

  Escuin, Daniel ^a,f   Burke, Patricia A ^b   McMahon Tobin, Grainne ^b   Hembrough, Todd ^b   Wang, Yuefang ^c   Alcaraz, Ana A ^d   Leandro García, Javier Luis ^e   Rodríguez Antona, Cristina ^e   Snyder, James P ^d   LaVallee, Theresa M ^b   Giannakakou, Paraskevi ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ENTREMED INC   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e Structural Biology and Biocomputing Programme   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

2ME2; Hematopoiesis; Myelosuppression; Taxanes; Tubulin; Tubulin isotypes

Indexed keywords

2 METHOXYESTRADIOL; BETA TUBULIN; COLCHICINE; COMBRETASTATIN; DOCETAXEL; EPOTHILONE B; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; 2-METHOXYESTRADIOL; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DRUG DERIVATIVE; ESTRADIOL; ISOPROTEIN; TAXANE; TAXOID; TUBULIN; TUBULIN MODULATOR;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; EPITHELIUM CELL; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC TISSUE; HUMAN; HUMAN CELL; MALE; MICROTUBULE; MICROTUBULE ASSEMBLY; MISSENSE MUTATION; MOUSE; MUTATION; NONHUMAN; PROTECTION; STEM CELL; TARGET CELL; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; HEMATOPOIESIS; METABOLISM; MOLECULAR GENETICS;

MUS; VINCA;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; ESTRADIOL; HEMATOPOIESIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICROTUBULES; MOLECULAR SEQUENCE DATA; PROTEIN ISOFORMS; STEM CELLS; TAXOIDS; TUBULIN; TUBULIN MODULATORS;

EID: 74849119557     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.23.10105     Document Type: Article

References (48)

1. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003; 3:363-75.
2. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007; 25:41-8.
3. Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, et al. Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res 2007; 13:6162-7.
4. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005; 11:6625-33.
5. Kirkpatrick J, Desjardins A, Quinn J, Rich J, Vredenburgh J, Sathornsumetee S, et al. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nanocrystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. ASCO Meeting Abstracts 2007;25:2065.
6. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-7.
7. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994; 91:3964-8.
8. Hamel E, Lin CM, Flynn E, D'Amato RJ. Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerized tubulin and with tubulin polymers. Biochemistry 1996; 35:1304-10.
9. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol 2003; 4:938-47.
10. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCRABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7:345-56.
11. Giannakakou P, Snyder JP. Resistance to Microtubule-Targeting Drugs In: Fojo AT, ed. Cancer Drug Discovery and Development: "The Role of Microtubules in Cell Biology, Neurobiology and Oncology". Totowa, NJ: Humana Press Inc 2008; 357-94.
12. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-25.
13. Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCIAnticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001;7:2912-22.
14. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428:198-202.
15. Luduena RF. Are tubulin isotypes functionally significant. Mol Biol Cell 1993; 4:445-57.
16. Sullivan KF. Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 1988; 4:687-716.
17. Sullivan KF, Cleveland DW. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc Natl Acad Sci USA 1986; 83:4327-31.
18. Shanker N, Kingston DG, Ganesh T, Yang C, Alcaraz AA, Geballe MT, et al. Enhanced microtubule binding and tubulin assembly properties of conformationally constrained paclitaxel derivatives. Biochemistry 2007;46:11514-27.
19. Lewis SA, Gu W, Cowan NJ. Free intermingling of mammalian beta-tubulin isotypes among functionally distinct microtubules. Cell 1987; 49:539-48.
20. Battinelli EM, Hartwig JH, Italiano JE Jr. Delivering new insight into the biology of megakaryopoiesis and thrombopoiesis. Curr Opin Hematol 2007; 14:419-26.
21. Italiano JE Jr, Patel-Hett S, Hartwig JH. Mechanics of proplatelet elaboration. J Thromb Haemost 2007;5:18-23.
22. Lecine P, Italiano JE Jr, Kim SW, Villeval JL, Shivdasani RA. Hematopoietic-specific beta1tubulin participates in a pathway of platelet biogenesis dependent on the transcription factor NF-E2. Blood 2000; 96:1366-73.
23. Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008; 132:631-44.
24. Kang SH, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006;66:11991-7.
25. Biermann H, Pietz B, Dreier R, Schmid KW, Sorg C, Sunderkotter C. Murine leukocytes with ring-shaped nuclei include granulocytes, monocytes and their precursors. J Leukoc Biol 1999; 65:217-31.
26. Rajkumar SV, Lacy MQ, Kyle RA. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Rev 2007; 21:255-65.
27. Domen J, Gandy KL, Weissman IL. Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 1998; 91:2272-82.
28. Meng A, Wang Y, Brown SA, Van Zant G, Zhou D. Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms. Exp Hematol 2003; 31:1348-56.
29. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65.
30. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7:107-17.
31. Italiano JE Jr, Bergmeier W, Tiwari S, Falet H, Hartwig JH, Hoffmeister KM, et al. Mechanisms and implications of platelet discoid shape. Blood 2003; 101:4789-96.
32. Schwer HD, Lecine P, Tiwari S, Italiano JE Jr, Hartwig JH, Shivdasani RA. A lineage-restricted and divergent beta-tubulin isoform is essential for the biogenesis, structure and function of blood platelets. Curr Biol 2001; 11:579-86.
33. Nogales E, Wolf SG, Downing KH. Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998; 391:199-203.
34. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in betatubulin: a model based on electron crystallographic density. Proc Natl Acad Sci USA 2001; 98:5312-6.
35. Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 2007; 7:704-12.
36. Seve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008; 9:168-75.
37. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003; 56:45-56.
38. Escuin D, Kline ER, Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 2005; 65:9021-8.
39. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107-12.
40. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T. Combinations of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 1998; 75:57-63.
41. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74.
42. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
43. Maestro 7.5. Schrodinger LLC. New York NY 2006.
44. Thomas AH. MMFF VI. MMFF94s option for energy minimization studies. Journal of Computational Chemistry 1999; 20:720-9.
45. Thomas AH. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. Journal of Computational Chemistry 1999; 20:730-48.
46. Still WC, Tempczyk A, Hawley RC, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990; 112:6127-9.
47. Omega 2.2.1. OpenEye Scientific Software Inc., Santa Fe NM 2007.
48. ROCS 2.3.1. OpenEye Scientific Software Inc., Santa Fe NM 2007.